Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label extension trial to assess the safety of long-term treatment of rotigotine CDS [continuous delivery system] in subjects with early stage, idiopathic Parkinson's disease (part II of double blind SP513).

Next Previous
Trial Profile

An open-label extension trial to assess the safety of long-term treatment of rotigotine CDS [continuous delivery system] in subjects with early stage, idiopathic Parkinson's disease (part II of double blind SP513).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors UCB

Most Recent Events

  • 08 Jun 2017 Results of post hoc analysis of pooled data from 6 placebo contolled trials (SP506, SP512, SP513, SP515, SP650, and SP921) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
  • 18 Jun 2015 Post hoc pooled analysis (SP702, SP716 and preceding double-blind trials) of 6-month earlier treatment initiation on long-term outcome; results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
  • 20 Apr 2015 Post-hoc analysis of pooled data presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), according to a UCB media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top